ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2001
Zanamivir: from drug design to the clinic.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1.Acta pharmaceutica Sinica. B · 2026Article
- Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Antiviral Approaches against Influenza Virus.Clinical microbiology reviews · 2023Review
- Rational Design of Novel Inhibitors of α-Glucosidase: An Application of Quantitative Structure Activity Relationship and Structure-Based Virtual Screening.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Lack of selective resistance of influenza A virus in presence of host-targeted antiviral, UV-4B.Scientific reports · 2019Article
- Toward development of generic inhibitors against the 3C proteases of picornaviruses.The FEBS journal · 2019Article
- Discovery of Influenza A virus neuraminidase inhibitors using support vector machine and Naïve Bayesian models.Molecular diversity · 2016Article
- Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats.Biomolecules & therapeutics · 2013Article
- Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child.Emerging infectious diseases · 2011Article
- Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.Clinical pharmacokinetics · 2010Review
- Influenza is now a preventable disease.International journal of antimicrobial agents · 2006Review
- A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.The Journal of antimicrobial chemotherapy · 2004Review
- Application of computational methods for anticancer drug discovery, design, and optimization.Boletin medico del Hospital Infantil de MexicoReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of the neuraminidase inhibitors has revolutionized the management options for influenza. Zanamivir was the first such inhibitor to be approved for the treatment of influenza in humans. It is delivered by inhalation to the respiratory tract, which is the site of viral replication, in order to ensure immediate antiviral activity. Early treatment with zanamivir in clinical trials rapidly reduced the severity and duration of influenza symptoms and associated complications. Furthermore, chemoprophylaxis with zanamivir was shown to be effective in the prevention of influenza illness. To date, there is no evidence for the emergence of clinically significant zanamivir-resistant isolates. In conclusion, zanamivir offers a useful complementary strategy to vaccination in the effective management of influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.